

other embodiments the poly-G nucleic acid comprises the following formula:

5' GGGNGGGNGGG 3' (SEQ ID NO:849) wherein N represents between 0 and 20 nucleotides.

Substitute the following paragraph for the existing paragraph at page 39, lines 10-19:

In some embodiments N_1 and N_2 of the nucleic acid do not contain a CCGG or CGCG quadmer or more than one CCG or CGG trimer. The effect of a CCGG or CGCG quadmer or more than one CCG or CGG trimer depends in part on the status of the nucleic acid backbone. For instance, if the nucleic acid has a phosphodiester backbone or a chimeric backbone the inclusion of these sequences in the nucleic acid will only have minimal if any affect on the biological activity of the nucleic acid. If the backbone is completely phosphorothioate or significantly phosphorothioate then the inclusion of these sequences may have more influence on the biological activity or the kinetics of the biological activity, but compounds containing these sequences are still useful. In another embodiment the CpG nucleic acid has the sequence 5' TCN₁TX₁X₂CGX₃X₄ 3' (SEQ ID NO:850).

Substitute the following paragraph for the existing paragraph at page 40, line 25 – page 41, line 7:

Poly G nucleic acids preferably are nucleic acids having the following formulas:

5' X₁X₂G₃G₄X₃X₄ 3'

wherein X₁, X₂, X₃, and X₄ are nucleotides. In preferred embodiments at least one of X₃ and X₄ are a G. In other embodiments both of X₃ and X₄ are a G. In yet other embodiments the preferred formula is 5' GGGNGGG 3', or 5' GGGNGGGNGGG 3' (SEQ ID NO:849) wherein N represents between 0 and 20 nucleotides. In other embodiments the poly-G nucleic acid is free of unmethylated CG dinucleotides, such as, for example, the nucleic acids listed in Table 4 below as SEQ ID NOs: 12-14, 23, 56, 100, 155, 163, 182, 227, 237, 246, 400, 407, 429, 430, 432, 435, 438, 439, 446, 450, 451, 480, 487, 493, 522, 661, 662, 671-673, 807, 808, 821, 823, and 834. In other embodiments the poly-G nucleic acid includes at least one unmethylated CG

β^y
dinucleotide, such as, for example, the nucleic acids listed in Table 4 below as SEQ ID NOs: 6, 7, 22, 26, 28-30, 87, 115, 141, 177, 191, 209, 254, 258, 267, 303, 317, 329, 335, 344, 345, 395, 414, 417, 418, 423-426, 428, 431, 433, 434, 436, 437, 440, 442-445, 447-449, 458, 460, 463, 467-469, 474, 515, 516, 594, 638-640, 663, 664, 727, 752, 776, 795, 799, 817, 818, 831, and 832.

Substitute the enclosed substitute Sequence Listing for the Sequence Listing filed with the application on June 22, 2001. A substitute computer readable form (CRF) of the substitute Sequence Listing is filed herewith, along with a Statement Under 37 C.F.R. § 1.821(f).

Election

In response to the Restriction Requirement in the same Office Communication, Applicants hereby elect Group I (claims 1-21, 34, 43, and 56) for examination. Applicants traverse the Restriction insofar as the characterization by the Examiner of Group I (claims 1-21, 34, 43, and 56) and of Group III (claims 24, 34, 43, and 56) appears in each instance to narrow improperly the scope of claims 34, 43, and 56. In particular, claims 34, 43, and 56 are not limited to an anti-CD20 antibody as suggested by the Examiner in characterizing Group I. Furthermore, 34, 43, and 56 are not limited to an anti-CD22 and an anti-CD19 antibody as suggested by the Examiner in characterizing Group III.

Applicants thus respectfully request that the Examiner not limit the scope of claims 34, 43, and 56, under present election of Group I, to an anti-CD20 antibody. In addition, for clarification in any future divisional application directed to Group III, Applicants request that the Examiner not limit the scope of claims 34, 43, and 56 to an anti-CD22 and an anti-CD19 antibody.

Remarks

The specification has been amended at pages 9, 39, and 40-41 to associate two sequences with SEQ ID NOs (SEQ ID NO:849 and SEQ ID NO:850) where the two sequences had not previously been assigned SEQ ID NOs. Accordingly, a substitute Sequence Listing is provided